FDA expands use of Zoryve to include young children with plaque psoriasis

The U.S.

Food and Drug Administration has approved an expanded indication for Zoryve (roflumilast) cream, 0.3%, for the topical treatment of plaque psoriasis in patients ages 2 and older.

The expanded approval was granted to Arcutis Biotherapeutics. ...